Biological properties of novel ruthenium- and osmium-nitrosyl complexes with azole heterocycles
Since the discovery that nitric oxide (NO) is a physiologically relevant molecule, there has been great interest in the use of metal nitrosyl compounds as antitumor pharmaceuticals. Particularly interesting are those complexes which can deliver NO to biological targets. Ruthenium- and osmium-based compounds offer lower toxicity compared to other metals and show different mechanisms of action as well as different spectra of activity compared to platinum-based drugs. Novel ruthenium- and osmium-nitrosyl complexes with azole heterocycles were studied to elucidate their cytotoxicity and possible interactions with DNA. Apoptosis induction, changes of mitochondrial transmembrane potential and possible formation of reactive oxygen species were investigated as indicators of NO-mediated damage by flow cytometry. Results suggest that ruthenium- and osmium-nitrosyl complexes with the general formula (indazolium)[cis/trans-MCl4(NO)(1H-indazole)] have pronounced cytotoxic potency in cancer cell lines. Especially the more potent ruthenium complexes strongly induce apoptosis associated with depolarization of mitochondrial membranes, and elevated reactive oxygen species levels. Furthermore, a slight yet not unequivocal trend to accumulation of intracellular cyclic guanosine monophosphate attributable to NO-mediated effects was observed.
KeywordsRuthenium Nitrosyl complexes Cancer Apoptosis cGMP level
Carbonyl cyanide 3-chlorophenylhydrazone
Cyclic guanosine monophosphate
- DCFH DA
Nuclear factor kappa-light-chain-enhancer of activated B cells
Reactive oxygen species
Soluble guanylate cyclase
Nitric oxide releasing (pro)drugs of an organic (nitroglycerin) and inorganic (sodium nitroprusside) kind were already in clinical use for decades before the discovery that such a small molecule could act as a signaling molecule in biological systems [13, 14, 15]. In recent years, several classes of exogenous NO donors have been synthesized with the aim to investigate physiological processes controlled by different concentrations of nitric oxide in the cell. Some research groups studied the photochemistry of such compounds, and various strategies were developed to activate these compounds to release NO under the influence of visible or UV/IR light . Generally, ruthenium nitrosyl complexes are attractive because of the thermal stability of the Ru–NO bond, which upon photochemical or electrochemical stimulation may release NO [17, 18, 19, 20, 21]. Besides this, it was proposed that the high affinity of NO to ruthenium might play a role in the mechanism of action of KP1019, which may act as an NO scavenger.
Materials and methods
Cell lines and culture conditions
CH1/PA-1 cells (identified via STR profiling as PA-1 ovarian teratocarcinoma cells by Multiplexion, Heidelberg, Germany; compare Ref. ) were obtained from Lloyd R. Kelland, CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, UK. SW480 (human adenocarcinoma of the colon), A549 (human non-small cell lung cancer) and HL-60 (human promyelocytic leukemia) cells were kindly provided by the Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Austria. All cell culture media and supplements were purchased from Sigma-Aldrich, Austria and plastic ware from Starlab, Germany. Cells were grown in 75 cm2 culture flasks in complete medium (i.e., Minimum Essential Medium supplemented with 10 % heat-inactivated fetal bovine serum, 1 mM sodium pyruvate, 4 mM l-glutamine and 1 % non-essential amino acids from 100× ready-to-use stock) as adherent monolayer cultures. Cultures were grown at 37 °C under a humidified atmosphere containing 5 % CO2 and 95 % air.
Antiproliferative activity in vitro was determined by the colorimetric MTT assay (MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide). For this purpose, cells were harvested from culture flasks by use of trypsin and seeded in complete medium (100 µL/well) into 96-well plates in densities of 3 × 103 (A549), 1 × 103 (CH1/PA-1) and 2 × 103 (SW480) cells per well. Cells were allowed for 24 h to settle and resume proliferation. Test compounds were dissolved in DMSO first, appropriately diluted in complete medium and instantly added to the plates (100 µL/well), where the DMSO content did not exceed 0.5 %. After exposure for 96 h, the medium was removed and replaced with 100 μL/well of a 1:7 MTT/RPMI 1640 solution (MTT solution, 5 mg/mL of MTT reagent in phosphate-buffered saline; RPMI 1640 medium, supplemented with 10 % heat-inactivated fetal bovine serum and 4 mM l-glutamine) and incubated for 4 h at 37 °C. Subsequently, the MTT/RPMI 1640 solution was removed, and the formazan product formed by viable cells was dissolved in DMSO (150 µL/well). Optical densities were measured with a microplate reader (BioTek ELx808) at 550 nm (and a reference wavelength of 690 nm) to yield relative quantities of viable cells as percentages of untreated controls, and 50 % inhibitory concentrations (IC50) were calculated by interpolation. Evaluation is based on at least three independent experiments with triplicates for each concentration level.
Neutral red uptake assay
Additionally, cell viability in vitro was investigated by the neutral red uptake assay (neutral red = 3-amino-7-dimethylamino-2-methylphenazine hydrochloride, Sigma). A549, CH1/PA-1 and SW480 cells were seeded in complete medium (100 µL/well) into 96-well plates in the same densities as for MTT tests and were allowed for 24 h to settle and resume proliferation. Test compounds 1c and 1t were dissolved in DMSO first, appropriately diluted in complete medium and instantly added to the plates (100 µL/well), where the DMSO content did not exceed 0.5 %. After expose for 96 h, medium was replaced with 100 µL/well of a neutral red-containing medium. A neutral red stock solution (5 mg/mL) was prepared in phosphate-buffered saline, then diluted 1:100 in RPMI 1640 medium (supplemented with 10 % heat-inactivated fetal bovine serum and 4 mM l-glutamine) and pre-incubated overnight at 37 °C. Plates were incubated with this neutral red solution for 2 h at 37 °C to allow for the uptake into the lysosomes of viable cells. After incubation the medium was removed, cells were washed with phosphate-buffered saline two times (150 µL/well) and fixed with 1 % acetic acid in 70 % ethanol (150 µL/well). After incubation for 10 min at RT, the absorption was measured with a microplate reader (BioTek ELx808) at 550 nm (and a reference wavelength of 690 nm) to yield relative quantities of viable cells as percentages of untreated controls, and 50 % inhibitory concentrations (IC50) were calculated by interpolation. Evaluation is based on at least three independent experiments with triplicates for each concentration level.
Impact on mitochondrial membrane potential (JC-1 assay)
Impairment of mitochondrial transmembrane potential was studied by flow cytometry using the lipophilic cationic dye 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolyl-carbocyanine iodide (JC-1). For this purpose, SW480 cells were exposed to test compounds in different concentrations for 48 h at 37 °C and then collected in a density of 2 × 105 cells/mL by centrifugation at 500g for 5 min. Afterwards, cells were washed with PBS and stained with 2 µg/mL JC-1 mix in complete medium for 15 min in the dark at 37 °C. Then cells were washed and suspended in 500 µL of warm PBS and analyzed with a Guava 8HT EasyCyte flow cytometer (Millipore) using InCyte software. Carbonyl cyanide 3-chlorophenylhydrazone (CCCP) was used as a positive control in a concentration of 0.9 mM.
Flow cytometric detection of apoptotic cells
Induction of cell death was analyzed by flow cytometry using FITC-conjugated annexin V (BioVision, USA) and propidium iodide (PI, Fluka) double staining. SW480 cells were seeded into 12-well plates in a density of 5 × 104 cells per well in complete medium and allowed to settle for 24 h. The cells were exposed to test compounds in different concentrations for 48 h at 37 °C. The platinum complex KP1988 (synthesized at the Institute of Inorganic Chemistry, University of Vienna) was used as a positive control in a concentration of 200 μM. After incubation, cells were gently trypsinized, washed with PBS, and suspended with FITC-conjugated annexin V (0.25 μg/mL) and PI (1 μg/mL) in binding buffer (10 mM HEPES/NaOH pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) at 37 °C for 15 min. Stained cells were analyzed with a Guava 8HT EasyCyte flow cytometer (Millipore) using InCyte software.
Detection of intracellular reactive oxygen species (ROS)
For the fluorimetric analysis of ROS, non-adherent HL60 cells (promyelocytic leukemia, human) were stained for 30 min at 37 °C under 5 % CO2 with 1 μM DCF-DA (2′,7′-dichlorofluorescein diacetate) in Hanks’ Balanced Salt Solution supplemented with 1% heat-inactivated fetal bovine serum. Cells were transferred into 96-well plates in a density of 6 × 104 cells/well and treated with the test substances at different concentrations for 30 min at 37 °C under 5 % CO2. A freshly prepared 500 μM H2O2 solution was used as a positive control and added 10 min before measurement. Cellular ROS levels were measured by flow cytometry on a Guava 8HT EasyCyte flow cytometer (Millipore). The resulting histograms of green fluorescence were quantified by FlowJo software (Tree Star). Results are presented as the ratios of green fluorescence intensities of the drug-treated samples and that of the untreated control.
Competition enzyme-linked immunoassay (cGMP assay)
The intracellular cGMP levels after treatment with nitrosyl complexes were assessed by using the Cyclic GMP XP™ Assay Kit (Cell Signaling Technology). The teratocarcinoma cell line CH1/PA-1 was grown in 12-well plates under standard conditions and treated with various concentrations of test compounds for 2 h. Then, cells were solubilized in lysis buffer, and intracellular cGMP levels were assessed according to manufacturer’s instructions. The absorbance was measured with a microplate reader (BioTek ELx808) at 450 nm, and the absolute amount of cGMP in samples was calculated by using a standard curve. Evaluation is based on at least three independent experiments with duplicates for each concentration level.
Plasmid DNA interaction studies
pUC19 DNA (2686 bp) plasmid was purchased from Fermentas Life Sciences. 500 ng of pUC19 plasmid was incubated with 50 μM of the test compounds in 0.1× Tris-EDTA (TE) buffer for different time intervals (5 min up to 6 h) at 37 °C. The electrophoresis was performed in agarose (from Sigma-Aldrich) gel 1 % w/v in 1× Tris-borate-EDTA (TBE) buffer for 90 min at 80 V. Gels were stained with ethidium bromide (EtBr) in 1× TBE (0.75 μg/mL) for 20 min. Images were taken with the multi-imaging detection system Fusion SL (Vilber Lourmat).
Results and discussion
Inhibition of cancer cell growth by studied compounds in three human cancer cell lines; 50 % inhibitory concentrations (means ± standard deviations), obtained by the MTT assay and neutral red uptake assay (exposure time: 96 h)
IC50, µM (MTT)a
IC50, µM (neutral red)
14 ± 3
2.7 ± 0.6
2.6 ± 0.3
20 ± 8
5.7 ± 2.5
4.3 ± 1.7
8.0 ± 1.3
1.3 ± 0.3
1.1 ± 0.3
9.3 ± 2.9
2.3 ± 0.7
1.5 ± 0.4
128 ± 18
48 ± 13
43 ± 6
145 ± 12
450 ± 35
The strongest difference in cytotoxicity was observed between trans-configured ruthenium indazole complex 1t and its osmium analog 2t with a maximum factor of about 400. The difference between the corresponding cis isomers 1c and 2c was also pronounced with a maximum factor of 18. In addition, the trans-configured ruthenium complex 1t is up to 2.4-fold more potent than its cis analog 1c, while the cis-configured osmium indazole complex 2c is up to tenfold more potent than its trans isomer 2t. For comparison, the antiproliferative activity of KP1019 tested previously yielded IC50 values of 44 ± 11 µM in CH1/PA-1 and 79 ± 5 in SW480 cells . Obviously, the exchange of one indazole present in KP1019 by NO increased the cytotoxic potency of ruthenium-based nitrosyl analog 1t about 72 times in SW480 and about 34 times in CH1/PA-1 cells.
The first cytotoxicity tests had been performed using the MTT assay, which is based on the reduction of a tetrazolium salt to an insoluble formazan, reflecting the number of viable cells present. This reduction is catalyzed by mitochondrial enzymes as well as by cytoplasmic and cell membrane components . Since nitric oxide can disrupt the mitochondrial respiratory system, the NO-mediated damage of mitochondria might distort the results of MTT-based cytotoxic tests. Therefore, the activity of the most active compounds was confirmed by the neutral red uptake assay. This assay is based on the ability of viable cells to incorporate and bind the neutral red dye into lysosomes and likewise provides a quantitative estimation of the number of viable cells .
IC50 values obtained by the neutral red uptake assay are systematically slightly higher than those obtained by the MTT assay, with a maximum factor of 2.1 (for 1c in CH1/PA-1 cells). However, these differences are too small to be taken as an indication for distortion of MTT-based cytotoxicity data by NO-mediated mitochondrial damage upon treatment with the tested substances.
The interactions with plasmid DNA had been studied previously for KP1019, showing its ability to untwist and to bend DNA . As analogs of KP1019, the nitrosyl complexes were now studied for their ability to interact with DNA. Cell-free experiments showed no significant activity versus a dsDNA plasmid (Fig. S1). These experiments suggest that ruthenium- and osmium-based nitrosyl complexes are unable to induce DNA damage under the experimental conditions.
In summary, the metal center variation and cis/trans isomerism in nitrosyl complexes bearing azole heterocycles have an unexpectedly large impact on their potency in human cancer cell lines. Generally, ruthenium nitrosyl complexes showed a stronger capacity to inhibit cancer cell proliferation, to induce depolarization of mitochondrial membranes and apoptosis, and to increase intracellular ROS and cGMP levels than the osmium analogs. Overall, the cis-configured ruthenium nitrosyl complex is nearly as potent as the trans-configured complex except for ROS and cGMP assays.
The observed stronger activity of ruthenium complexes is remarkable and can be explained by differences in M–NO bond stabilities. There is evidence that the Os–NO bond is stronger compared to the Ru–NO analog . As a consequence, the ruthenium compounds are prone to reduction in the biological environment due to the decreased stabilization of the NO ligand compared to the Os counterparts. Furthermore the ruthenium analogs can be activated by ascorbic acid, leading to hydrolysis of one chloride ligand in contrast to osmium analogs . Ford has pointed out a “trans-effect” for ruthenium nitrosyls, which was more recently reviewed for octahedral transition metal complexes in general by Coe and Glenwright [18, 41]. Ford claims that the identity of the trans-ligand affects the M–NO and N–O stretching frequencies; notably, X-ray structures of ruthenium nitrosyls showed that in the trans position the M–ligand bond was significantly longer than in the cis-position. This is in line with previous research where it was shown that Ru−NO bonds in the cis isomer 1c are significantly shorter than in the trans isomer 1t because of the stronger trans effect of indazole compared to the chlorido ligand . This is also confirmed by thermodynamic data showing a preference for the cis compound: cis to trans isomerization [−18.6 J/(mol K)] and [31.0 J/(mol K)] for the trans to cis conversion. Kinetic data reveal the same picture with rate constants of 5.51 × 10−6 for the cis→trans process and 12.2 × 10−6 for the trans→cis process at 100 °C in an aprotic solvent .
We come to the point that the understanding of the intracellular Ru–NO bond behavior is crucial for structure–activity relationships of this class of metallodrugs. If we take into account that the Ru–NO bond is more labile than the Os–NO bond, we may expect the release of NO under biological conditions as mentioned above. The role of NO in mitochondria-mediated cell death was reported several times before. Brown and co-workers describe a broad range of NO actions on mitochondria: it inhibits mitochondrial respiration, stimulates the production of superoxide, hydrogen peroxide and peroxynitrite, induces the transition permeability and release of cytochrome C, and NO potentially sensitizes cells to hypoxic damage . Toledo et al. reported the ability of ruthenium(II) ammine nitrosyl complexes to release NO under biological conditions, where the reduction of these complexes is concomitant with mitochondrial NADH oxidation . Curti and co-authors also observed NO release for this compound class which was occurring as a result of NAD(P)H oxidation and led to dissipation of mitochondrial membrane potential, ATP depletion and generation of ROS. As described in the most recent publication, oxidation of mitochondrial NADH promotes NO release from nitrosyl ruthenium complexes, which is accompanied by the release of cytochrome C [43, 44].
Thus far, our results demonstrate that the studied ruthenium nitrosyl complexes induce apoptosis by the mitochondrial pathway, at least partially associated with ROS generation, and may represent promising drug candidates for further preclinical evaluation.
Austrian Science Fund (FWF). We are deeply grateful to Prof. Dr. Vladimir Arion for overall support and collaborations. Authors wish to thank Anatolie Gavriluta (Université Claude Bernard Lyon 1, France) for cooperation. This work was performed as part of an Austrian-French joint project supported in France by ANR (Agence Nationale de la Recherche) through the project VILYGRu (No. ANR-09-BLAN-0420-01) and in Austria by the Austrian Science Fund (FWF) through the project I374-N19. Partial support by the Austrian Science Fund through the project P-22339-N19 is also acknowledged.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest regarding the contents of this article.
- 8.Bergamo A, Sava G (2007) Dalton Trans 1267–1272Google Scholar
- 9.Thompson DS, Weiss GJ, Jones SF, Burris HA, Ramanathan RK, Infante JR, Bendell JC, Ogden A, Von Hoff DD (2012) J Clin Oncol 30 (suppl; abstr 3033) Google Scholar
- 12.Jakupec MA, Kandioller W, Alte B, Trondl R, Berger W, Keppler BK (submitted manuscript) Google Scholar
- 40.Cleare MJ (1968) Platinum Met Rev 12:131–133Google Scholar
- 42.Toledo JC Jr, Lopes LG, Alves AA, Pereira da Silva L, Franco DW (2002) J Inorg Biochem 89(3–4):267–271Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.